PMID- 2711381
OWN - NLM
STAT- MEDLINE
DCOM- 19890602
LR  - 20190727
IS  - 0040-8727 (Print)
IS  - 0040-8727 (Linking)
VI  - 157
IP  - 2
DP  - 1989 Feb
TI  - Almitrine bismesylate reduces hypoxic pulmonary vasoconstriction in isolated rat 
      lungs.
PG  - 119-29
AB  - The purpose of this study is to test how almitrine bismesylate (Alm) affects the 
      function of pulmonary vasculature during normoxic ventilation, and whether low 
      doses of Alm not causing detectable vasoconstriction during normoxic ventilation 
      potentiate hypoxic pulmonary vasoconstriction (HPVC). Isolated Wistar male rat 
      lungs were perfused with homologous blood at constant flow, and venous and 
      ventilatory pressure. In the first experiment, after equilibration, dose-response 
      curves to Alm (from 0 to 1000 ng/ml, n = 10) were measured under the ventilation 
      with normoxic gas mixture (21% O2, 5% CO2, 74% N2). It was found that Alm causes 
      a dose-dependent pulmonary vasoconstriction. In the second experiment, low doses 
      of Alm (125 mg/ml) or diluent of Alm (malic acid) was injected to the blood 
      reservoir. This doses of Alm did not cause significant vasoconstriction during 
      normoxic gas ventilation compared with malic acid. After stabilization of 
      pulmonary arterial pressure, the lungs were exposed to three cycles of normoxia 
      (10 min) and hypoxia (10 min) through ventilation with gas containing 21% or 2% 
      O2 and 5% CO2. It was observed that low doses of Alm significantly reduce HPVC (p 
      less than 0.05) on the later periods of the first and the second hypoxic 
      challenges. However, no significant difference was revealed among two groups in 
      the third hypoxic challenge. Directly measured blood Alm concentration was 
      significantly lower in the third challenge than in the first challenge. Responses 
      to angiotensin II were not decreased by Alm. In conclusion, high doses of Alm 
      constrict pulmonary vasculature dose-dependently, and low doses of the drug not 
      causing vasoconstriction during normoxia reduce HPVC in rat.
FAU - Kato, S
AU  - Kato S
AD  - First Department of Internal Medicine, Yamagata University School of Medicine.
FAU - Sato, S
AU  - Sato S
FAU - Takahashi, K
AU  - Takahashi K
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Tohoku J Exp Med
JT  - The Tohoku journal of experimental medicine
JID - 0417355
RN  - 0 (Piperazines)
RN  - 9A1222NBG4 (Almitrine)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Almitrine
MH  - Animals
MH  - Body Weight
MH  - Hemodynamics
MH  - In Vitro Techniques
MH  - Lung/*blood supply
MH  - Male
MH  - Oxygen/*pharmacology
MH  - Piperazines/blood/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Vasoconstriction/*drug effects
EDAT- 1989/02/01 00:00
MHDA- 1989/02/01 00:01
CRDT- 1989/02/01 00:00
PHST- 1989/02/01 00:00 [pubmed]
PHST- 1989/02/01 00:01 [medline]
PHST- 1989/02/01 00:00 [entrez]
AID - 10.1620/tjem.157.119 [doi]
PST - ppublish
SO  - Tohoku J Exp Med. 1989 Feb;157(2):119-29. doi: 10.1620/tjem.157.119.